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US perspective. METHODS: Techniques of decision analysis and
data from secondary sources were used to develop and estimate
an economic model of the management of uterine ﬁbroids among
premenopausal women. Patients in the model are assumed to
receive ﬁrst-line treatment with MRgFUS, myomectomy, uterine
artery embolization (UAE), hysterectomy, or pain medication
only. Additional rounds of treatment (up to three) for treatment
failure or recurrent ﬁbroids also were incorporated in the model.
The model predicts total costs and quality-adjusted life years
(QALYs) for each strategy over a lifetime horizon. Data on
treatment efﬁcacy and safety were obtained from published and
unpublished studies. Cost data (2005 US$) were estimated from
a large administrative database and supplemented with expert
opinion. Analyses incorporated both direct and indirect (lost
productivity) costs. RESULTS: UAE was associated with the
most discounted QALYs (17.39), followed by MRgFUS (17.36),
myomectomy (17.35), hysterectomy (17.18) and pain manage-
ment (16.70). Pain management was the least costly strategy
($9,200 per patient), followed by hysterectomy ($19,800),
MRgFUS ($27,300), UAE ($28,900), and myomectomy
($35,100). Incremental cost-effectiveness ratios (cost per QALY
gained) were $21,800 for hysterectomy, $41,400 for MRgFUS,
and $54,200 for UAE; myomectomy was both more costly and
less effective than MRgFUS and UAE (i.e., dominated). Sensitiv-
ity analyses indicated that results are sensitive to MRgFUS recur-
rence rates and procedure costs as well as assumptions about the
quality-of-life decrement following hysterectomy. CONCLU-
SION: Our ﬁndings suggest that, with the exception of myomec-
tomy, currently available treatment options for uterine ﬁbroids
(i.e., hysterectomy, UAE, MRgFUS) are in the range of currently
accepted criteria for cost-effectiveness. Any of them could be the
cost-effective choice, depending on patient preferences and
resource availability.
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OBJECTIVES: The purpose of this study was to evaluate the cost
effectiveness (cost utility) of idursulfase (Elaprase) treatment of
people with Mucopolysaccharidosis II in the UK. METHODS:
Mucopolysaccharidosis II (MPS II; also referred to as Hunter’s
Syndrome) is an ultra-orphan lysosomal storage disorder that
reveals itself around the age of 3 years and leads to disabling
clinical manifestations and early death. Enzyme replacement
therapy (ERT) using idursulfase was compared to palliative care,
as no other pharmacological treatment is available. A cost utility
cohort model was developed using utility assumptions drawn
from the literature. Data were derived where possible from the
idursulfase pivotal trial, from published literature and from his-
torical records of the UK MPS Society. Where data was not
available, reasonable assumptions were made, with varying sce-
narios employed as sensitivity analyses. Current palliative care
employs physiotherapy, oxygen and care by parents, but varies
by severity of the disease. This lack of consistent approach to
palliative care meant that no direct cost could be assigned. Due
to little clinical experience, only three disease states were con-
sidered: idursulfase-treated, palliative care, and death. The
maximum time horizon was 15 years to account for the chronic
nature of the disease and to encompass the beneﬁts of idursulfase
treatment, which are be expected to change the course of the
disease over the long term. Costs were calculated from UK 2007
prices. Costs and beneﬁts were discounted annually at 3.5%.
RESULTS: The model showed a discounted incremental cost
effectiveness ratio (ICER) over palliative care of GBP564,692 per
quality adjusted life year (QALY). Sensitivity analyses showed
that the two key drivers of the ICER are quality of life and
mortality. CONCLUSION: Although high, the ICER for MPS II
is consistent with other orphan diseases treated with ERT, such as
Gaucher’s and Fabry’s diseases.
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OBJECTIVES: The Fleetwood model is a holistic approach to
structured pharmaceutical care in the nursing home setting. It has
been adapted for use in the UK and is currently being tested in NI
in a randomised controlled trial. The aim of this study was to use
MDWS to provide estimates of resource usage for inclusion in a
cost model. METHODS: Pharmacists providing the adapted
Fleetwood pharmaceutical care service to nursing home residents
completed an activity classiﬁcation sheet (previously developed
and piloted), comprising 15 main categories. This provided infor-
mation on the type of activity undertaken, time taken and
whether it was related to ‘cycle 1’ (initial pharmaceutical care
plan development) or subsequent cycles. Data reported is for 9
pharmacists during the ﬁrst three cycles carried out in 11 inter-
vention homes. RESULTS: Actual resource utilisation was sig-
niﬁcantly different to estimates used to obtain funding. It was
estimated that ‘cycle 1’ would involve 3 hours of pharmacist time
per nursing home resident and last 30 days, and that each
subsequent cycle would involve 1 hour per month (30 days)
per resident. The actual total time spent was 46.1% of that
estimated, and the average cost per resident was 39%
(92.31  33.83 vs. 236.74  15.70). Signiﬁcantly more time
than estimated was required to complete a cycle; the longest cycle
length occurred in cycle 1 (170 days) with 30.2 hrs  5.16 spent
in each home delivering the service to 15.7  2.2 residents.
Semi-professional or non-professional activity accounted for
71.5% of total time in cycle 1. CONCLUSION: MDWS enabled
a more accurate picture of pharmacist activities and estimates of
time input for inclusion in the cost model. This information is
important in planning service development and delivery, as non-
or semi-professional activities could be delegated to pharmacy
support staff.
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OBJECTIVES: The practice of drug keeping in homes and self
medication is well recognised problem. The aim of our work was
to compare pharmacotherapeutical and pharmacoepidemiologi-
cal aspects of drug home cabinets in two countries with different
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